Poolbeg Pharma Future Growth
Future criteria checks 0/6
Poolbeg Pharma's earnings are forecast to decline at 13.8% per annum. EPS is expected to decline by 12.9% per annum.
Key information
-13.8%
Earnings growth rate
-12.9%
EPS growth rate
| Pharmaceuticals earnings growth | 14.7% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 11 Mar 2024 |
Recent future growth updates
No updates
Recent updates
We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Feb 16
We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Oct 05We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Jun 01Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation
Jul 12Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2024 | N/A | -6 | -6 | -6 | 2 |
| 12/31/2023 | N/A | -6 | -6 | -6 | 2 |
| 6/30/2023 | N/A | -5 | -5 | -5 | N/A |
| 3/31/2023 | N/A | -5 | -5 | -5 | N/A |
| 12/31/2022 | N/A | -5 | -5 | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: POLB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: POLB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: POLB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if POLB's revenue is forecast to grow faster than the UK market.
High Growth Revenue: POLB is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if POLB's Return on Equity is forecast to be high in 3 years time